Bristol-myers Squibb Compnay

Fmc Corporation

Yale University

Syngene International Limited

Natesan Murugesan

Zhengxiang Gu

William R Ewing

Ramesh Kumar Sistla

John T Hynes

Joel C Barrish

Chongqing Sun

Satheesh Kesavan Nair

Venkatram Reddy Paidi

John V Duncia

Joseph B Santella

Daniel S Gardner

Sreekantha Ratna Kumar

Bruce A Ellsworth

Hong Wu

Yanting Huang

John E Macor

Annapurna Pendri

Philip D Stein

Samuel Gerritz

William John Pitts

Philip Michael Sher

Rajeev S Bhide

John T Hunt

Richard B Sulsky

Susheel Jethanand Nara

Guixue Yu

Gang Wu

Kandhasamy Sarkunam

Doree F Sitkoff

Amarendra B Mikkilineni

John E Tellew

James Aaron Balog

John E Lloyd

Steven P Seitz

David K Williams

Weifang Shan

Audris Huang

Jay A Markwalder

Emily Charlotte Cherney

Srinivas Cheruku

Saumya Roy

Srinivasan Thangathirupathy

Soodamani Thangavel

Weiwei Guo

Ximao Wu

Nagalakshmi Pulicharla

Yadagiri Kanyaboina

Ying Wang

Chunjian Liu

Alicia Regueiro-Ren

Steven H Spergel

Gregory S Bisacchi

Pratik Devasthale

Taekyu Lee

Minsheng Zhang

Peter W Glunz

Keith Douglas Barnes

Yeheng Zhu

Todd J Friends

Manoranjan Panda

Prasada Rao Jalagam

John A Dixson

Navnath Dnyanoba Yadav

Jianxin Feng

Mandar Shrikrishna Bodas

Harry H Wasserman

Scott A Bolton

Mariano A Guiducci

Subba Rao Polimera

Gergory S Bisacchi

Joseph B Santella Iii

Stephen R Johnson

Richard A Morrison

John H Van Duzer

Durgarao Kantheti

Venu Alla

Piramanayagam Arunachalam

Leena Fadnis

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: Xand Xare independently C or N, provided that zero or one of Xand Xis N; Ring A represented by the structure is: or; and Q, R, R, R, R, R, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Tricyclic heteroaryl compounds useful as IRAK4 inhibitors

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 R; and R, R, and Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer. 

Heteroaryl substituted aminopyridine compounds

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Triazolones and tetrazolones as inhibitors of ROCK

Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

Heteroaryl substituted pyridyl compounds useful as kinase modulators

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

IDO inhibitors

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a monocyclic heteroaryl group, and R, R, R, Rand Rare as defined herein, are useful as kinase modulators, including IRAK-4 inhibition. 

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein Ris a bicyclic heterocycle, and R, R, R, Rand Rare as defined herein, that are useful as kinase modulators, including IRAK-4 modulation. 

Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH, or CH; Z is CH or N; Rand Rare hydrogen or (C-C)alkyl; Ris (C-C)alkoxy, OH, CN, (C-C)alkyl, halogen, or CF; r and s are 0, 1, or 2; and Rand Rare as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor. 

Substituted adipic acid amides and uses thereof

Disclosed are compounds of Formula (I) or salts thereof, wherein: HET is a heteroaryl selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-d]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl, imidazo[4,5-b]pyridinyl, and purinyl, wherein said heteroaryl is substituted with Rand R; and Rand Rare define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases.

Heteroaryl substituted nicotinamide compounds

The invention provides for compounds of formula I  Further provided are methods of using such compounds for the treatment of eating disorders, metabolic disorders, obesity, cognitive disorders, neurological disorders, pain disorders, inflammation disorders, in the promotion of smoking cessation and for the treatment of other psychiatric disorders Also provided are pharmaceutical compositions containing such compounds and pharmaceutical combinations of the compounds of the invention with other therapeutic agents.

Tetrahydroquinoline derivatives as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I. including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R, R, R, R, R, m and n are described herein.

Azabicyclic heterocycles as cannabinoid receptor modulators

Growing community of inventors

Princeton Junction, NJ, United States of America

Natesan Murugesan